Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Clinical Hospital Clinical of Barcelona, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“New Research Published!
I’m excited to share our latest work:
‘Ki67 dynamics predict endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy’
In this study conducted at the Breast Cancer Functional Unit of the Clínic Barcelona Comprehensive Cancer Center, we show that a short 2–12 week preoperative course of endocrine therapy (tamoxifen or aromatase inhibitor) can provide meaningful biological information about endocrine sensitivity.
Key findings:
- Ki67 suppression after short-course endocrine therapy is common (85%) and easily measurable in daily practice.
- Achieving complete cell cycle arrest (CCCA, Ki67 ≤2.7%) identifies patients with excellent outcomes (HR = 0.19; p = 0.012).
- Tumors with Luminal A subtype, high ER expression, and low ROR score show the strongest endocrine response.
These results support short preoperative endocrine therapy as a simple, feasible, and informative approach to assess endocrine sensitivity and potentially guide treatment de-escalation in ER+/HER2− early breast cancer.
Congratulations to Raquel Gómez Bravo and Benjamin Walbaum, and all co-authors for this excellent collaborative work, now published open access in ESMO Open!”
Title: Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy
Authors: R. Gómez-Bravo, B. Walbaum, M. Bergamino, O. Martínez-Sáez, F. Schettini, E. Seguí, I. García-Fructuoso, T. Pascual, N. Chic, M. González, A. Rodríguez, M. Rey, P. Giménez-Xavier, P. Blasco, O. Castillo, P. Galván, E. Sanfeliu, B. González-Farré, M. Vidal, B. Adamo, F. Brasó-Maristany, A. Prat, M. Muñoz
Read the Full Article on ESMO Open
More posts featuring Aleix Prat.
